TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Price & Overview
NYSE:TEVA • US8816242098
Current stock price
The current stock price of TEVA is 28.57 USD. Today TEVA is down by -2.49%. In the past month the price decreased by -15.77%. In the past year, price increased by 74.95%.
TEVA Key Statistics
- Market Cap
- 32.859B
- P/E
- 9.59
- Fwd P/E
- 10.16
- EPS (TTM)
- 2.98
- Dividend Yield
- N/A
TEVA Stock Performance
TEVA Stock Chart
TEVA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to TEVA. When comparing the yearly performance of all stocks, TEVA is one of the better performing stocks in the market, outperforming 89.49% of all stocks.
TEVA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TEVA. While TEVA belongs to the best of the industry regarding profitability, there are concerns on its financial health.
TEVA Earnings
On January 28, 2026 TEVA reported an EPS of 0.98 and a revenue of 4.71B. The company beat EPS expectations (38.54% surprise) and beat revenue expectations (5.75% surprise).
TEVA Forecast & Estimates
7 analysts have analysed TEVA and the average price target is 0.11 USD. This implies a price decrease of -99.61% is expected in the next year compared to the current price of 28.57.
For the next year, analysts expect an EPS growth of -5.45% and a revenue growth -0.99% for TEVA
TEVA Groups
Sector & Classification
TEVA Financial Highlights
Over the last trailing twelve months TEVA reported a non-GAAP Earnings per Share(EPS) of 2.98. The EPS increased by 17.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.16% | ||
| ROA | 3.46% | ||
| ROE | 17.81% | ||
| Debt/Equity | 1.9 |
TEVA Ownership
TEVA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.18 | 921.899B | ||
| JNJ | JOHNSON & JOHNSON | 20.74 | 583.292B | ||
| MRK | MERCK & CO. INC. | 22.34 | 286.575B | ||
| PFE | PFIZER INC | 8.9 | 152.733B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.05B | ||
| ZTS | ZOETIS INC | 16.34 | 48.739B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.461B | ||
| VTRS | VIATRIS INC | 5.39 | 15.889B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.81 | 11.276B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.883B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.361B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.698B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.9 | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TEVA
Company Profile
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Company Info
IPO: 1951-01-01
TEVA PHARMACEUTICAL-SP ADR
124 Dvora Hanevi'a St.
TEL AVIV-YAFO 49131 IL
CEO: Kare Schultz
Employees: 31173
Phone: 97239148213
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What does TEVA do?
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
What is the stock price of TEVA PHARMACEUTICAL-SP ADR today?
The current stock price of TEVA is 28.57 USD. The price decreased by -2.49% in the last trading session.
What is the dividend status of TEVA PHARMACEUTICAL-SP ADR?
TEVA does not pay a dividend.
What is the ChartMill technical and fundamental rating of TEVA stock?
TEVA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the market cap for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a market capitalization of 32.86B USD. This makes TEVA a Large Cap stock.
What is the next earnings date for TEVA stock?
TEVA PHARMACEUTICAL-SP ADR (TEVA) will report earnings on 2026-05-05.